FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 , = =	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Behbahani Ali</u>			2. Issuer Name and Ticker or Trading Symbol CRISPR Therapeutics AG [CRSP]									ck all applic	able)	g Pers	son(s) to Iss				
(Last) (First) (Middle) 1954 GREENSPRING DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 06/09/2022										Officer below)	(give title		Other (s below)	pecify		
SUITE 600			4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)								
(Street) TIMONI	UM M	D	21093											X		led by Mor		orting Person	- 1
(City)	(S	tate)	(Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transar Date (Month/D:				Execution Date,			3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)				4 and Securitie Beneficia		es Form ally (D) of following (I) (Ir		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code			v	Amount	(A) or (D) Price		ice	Transaction(s) (Instr. 3 and 4)				(III3ti. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
			ransad ode (li	ansaction of			6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)			ies g Secui	Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				C	ode	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amor or Num of Share	ber					
Stock Option (Right to Buy)	\$71.7	06/09/2022			A		12,000		(1)	0	6/09/2032	Common Shares	12,0	000	\$0.00	12,000)	D	

Explanation of Responses:

1. This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders.

Remarks:

/s/ Louis Citron, attorney-in-

fact

** Signature of Reporting Person Date

06/10/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.